Search clinical trials for: Glargine insulin

Total 2825 results

Eli Lilly and Company

Completed

A Study of LY900014 in Participants With Type 1 Diabetes (PRONTO-T1D)

Type 1 Diabetes Mellitus

Italy, Japan, United States, Puerto Rico, Spain, Taiwan, Mexico, Austria, Germany, Poland, New Zealand, Romania, Russian Federation, Argentina, India, Sweden, Slovakia, Australia, Brazil, Greece
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

China, Argentina, Mexico
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus

China, Mexico, Argentina
Tamra Dukatz
Sanofi

Completed

Perioperative Insulin Glargine Dosing Study

Diabetes | Surgery

United States
Rush University Medical Center

Withdrawn

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Type 2 Diabetes Mellitus
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2

Turkey
Sanofi

Completed

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

France, Russian Federation, Croatia, Slovenia, Czech Republic, Romania
AstraZeneca
Eli Lilly and Company

Completed

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Finland, Netherlands, Sweden
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
AstraZeneca
Eli Lilly and Company

Completed

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Type 2 Diabetes

United Kingdom
Fudan University
Shanghai Changzheng Hospital; Shanghai 6th People's Hospital; Shanghai Minhang... and other collaborators

Completed

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Non-alcoholic Fatty Liver Disease

China
Eli Lilly and Company

Completed

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes (PRONTO-Peds)

Type 1 Diabetes Mellitus

United States, Czechia, France, Spain, Japan, Germany, Italy, Brazil, Denmark, Austria, United Kingdom, China, Russian Federation, Mexico, Poland, Ukraine, Israel, Puerto Rico
Cliniques universitaires Saint-Luc- Université...

Completed

Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes (TREAD-DIAB)

Type 1 Diabetes

Belgium
Eli Lilly and Company

Completed

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (AUTONOMY)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Poland, Canada, Austria, Mexico, Denmark, Croatia, Brazil, Argentina, Romania, South Africa, Russian Federation, France, Lithuania
Sanofi

Completed

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) (AT-LANTUS)

Diabetes Mellitus, Type 1
Eli Lilly and Company

Completed

Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

Diabetes Mellitus, Type 2

Canada, India, Romania, Spain, Mexico, Turkey, Portugal, Egypt
AstraZeneca
Eli Lilly and Company

Completed

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Belgium, United States, Australia, Portugal, Germany, Puerto Rico, Spain, Netherlands, Brazil, Finland, Norway, Poland, Sweden
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

A Comparison of Exenatide and Insulin Glargine

Type 2 Diabetes

China
Riverside University Health System Medical Center

Terminated

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Type 2 Diabetes Mellitus

United States
Cairo University
Sanofi

Unknown

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial (VIRDICT)

Liver Cirrhosis | Type 2 Diabetes

Egypt
Emory University

Completed

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

Diabetes Mellitus | Type 1 Diabetes

United States
Eli Lilly and Company

Completed

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro

Diabetes Mellitus
Sanofi

Completed

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Diabetes Type 2

Sweden
Institut de Recherches Cliniques de Montreal
Novo Nordisk A/S; McMaster University

Completed

Levemir-Body Composition and Energy Metabolism

Type 2 Diabetes

Canada
Vancouver General Hospital

Terminated

Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (PTHG)

Post-Transplant Glucocorticoid Induced Diabetes

Canada
Assaf-Harofeh Medical Center

Terminated

Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward

Diabetes Mellitus

Israel
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

Diabetes Mellitus, Type 2

Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
Daiichi Sankyo, Inc.

Completed

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
University of Colorado, Denver

Completed

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

Type 1 Diabetes Mellitus | Diabetic Ketoacidosis

United States
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

Diabetes Mellitus

Sweden, Finland, Netherlands, United Kingdom
Loyola University
Sanofi

Completed

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Renal Insufficiency | Type 2 Diabetes

United States
Hoffmann-La Roche

Terminated

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Diabetes Mellitus Type 2

China, Hong Kong, Korea, Republic of, Philippines, Taiwan, Malaysia, Thailand
Dr. Muhammad Abdulghani

Unknown

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

Type 2 Diabetes

Qatar
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Type 2 Diabetes

China
Eli Lilly and Company

Completed

A Study of LY2963016 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Diabetes Mellitus

Singapore
Sanofi

Completed

Glycemic Optimization Treatment Study (GOT)

Diabetes Mellitus, Type 2
Amsterdam UMC, location VUmc

Completed

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

Obesity | Type 2 Diabetes

Netherlands
Eli Lilly and Company

Completed

Lispro Mix 25 vs. Glargine in Type 2 Diabetics (IOOL)

Diabetes Mellitus Type 2

Mexico
Eli Lilly and Company

Completed

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Eli Lilly and Company

Completed

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin (OPTIMIZATION)

Diabetes Mellitus, Type 2

China
Sanofi

Completed

20 Week Bridging Study in Type II DM

Diabetes Mellitus Type II

Search clinical trials for: Glargine insulin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations